A quick random search via Mr Chat GT on the Car T market
Just for what it is worth .....
Food for thought particularly if CHM's CDH 17 Allogenic work evolves to a point of being VERY Noticed
Can u tell me what the market size is of Car T cancer therapies in the USA ? What is the average cost of current standard of care Car T treatments per patient .
ChatGPT said:
ChatGPT
Searched 6 sites
The CAR T-cell therapy market in the United States was valued at approximately $1.85 billion in 2024 and is expected to grow significantly, potentially reaching $10.3 billion by 2034 due to increased adoption and continuous advancements in the field. This market growth is driven by high cancer incidence rates and substantial investment in research and development in the U.S., which leads to innovations and expanded therapy options for challenging cancers like lymphoma and multiple myeloma Fortune Business Insights Grand View Research
.
Regarding the cost of CAR T-cell therapy per patient, treatments typically range between $400,000 and $475,000 for drugs like Yescarta and Kymriah, which are used in treating aggressive B-cell lymphomas. However, in practice, the total expense can often exceed $700,000 when factoring in additional costs related to hospital stays, pre-treatment therapies, and managing adverse side effects Fortune Business Insights Prophecy Market Insights
.
4o
You said:
What is the likely cost of new Killer NK Cart T treatments under development & who leads the world in this filed
ChatGPT said:
ChatGPT
Searched 4 sites
CAR NK (Natural Killer) therapies, a next-generation approach to immunotherapy, show promise as an alternative to traditional CAR T-cell therapies. NK cell therapies are typically less expensive to develop than CAR T-cells due to the simpler manufacturing and reduced safety concerns, such as a lower risk of cytokine release syndrome (CRS). Early estimates suggest that CAR NK therapies may be commercially available at lower prices than CAR T-cell therapies, although specific cost figures are not fully determined yet as many CAR NK therapies remain in clinical trials and pre-commercial stages.
The leading developers in the CAR NK space include MD Anderson Cancer Center in partnership with Takeda, which is working on “off-the-shelf” CAR NK therapies designed for outpatient administration, targeting cancers like B-cell malignancies. Artiva Biotherapeutics, supported by Merck, focuses on scalable CAR NK therapies for both blood and solid tumors, aiming to streamline accessibility and reduce costs through a “manufacturing-first” approach. Additionally, companies like ONK Therapeutics and Fate Therapeutics are innovating in the use of umbilical cord blood-derived NK cells to target multiple cancer types efficiently Fortune Business Insights MD Anderson Cancer Center FierceBiotech PharmTech
.
These ongoing collaborations and advancements suggest that CAR NK therapies could become more accessible and affordable in the coming years, potentially making immunotherapy a more practical option for a broader patient base.
4o
You said:
How does Chimeric Therapeutics rate in the filed
ChatGPT said:
ChatGPT
Searched 3 sites
Chimeric Therapeutics is emerging as a notable player in CAR NK-cell therapy, leveraging its CORE-NK platform to develop allogeneic (off-the-shelf) NK cell therapies aimed at treating various cancers, including glioblastoma and other solid tumors. Their pipeline includes CAR NK therapies like CHM 1301 and CHM 2301, which are advancing through preclinical and early clinical stages with the potential for scalable, lower-cost production compared to traditional CAR T-cell treatments. These CAR NK therapies offer the advantage of being potentially less complex and more accessible than patient-specific therapies due to simpler manufacturing and fewer side effects like cytokine release syndrome (CRS) MD Anderson Cancer Center Chimeric v1.0
.
Globally, the CAR NK space is competitive, with key players like Artiva, Merck, and MD Anderson Cancer Center also advancing off-the-shelf NK-cell therapies designed to be more cost-effective and logistically feasible for widespread use. Chimeric's development strategies align closely with market leaders, focusing on a streamlined approach to bring NK-cell therapies to broader markets efficiently FierceBiotech PharmTech
. CHM has a market cap of 10 mill approx @ current pricing .
CHM Price at posting:
0.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)